CGT has the potential to transform medicine, providing long term and potentially curative treatment options for a wide range of diseases. Lentiviral vector is useful vehicle in delivering gene of interest (GOI) in cell and gene therapies, and therefore, the safety and stable manufacturing of LVV are drawing attention. GenScript ProBio is dedicated to developing adherent and suspension platform to support with the development and manufacturing of lentiviral vector.
Working within GMP regulations, GenScript ProBio offers cell banking manufacturing services to customers.
ProLentiviral Vector manufacturing is appropriate for the use in non-clinical phases, with both adherent and suspension culture systems.
One-stop solution covering process development, analytical development, suspension production, LVV Manufacturing GMP manufacturing and stability test to support regulatory filings.
GMP lentiviral vector is manufactured compliant to GMP regulations, suitable for early phase clinical trials.